title: Prostatic cell-specific regulation of the synthesis of MUC1-associated sialyl Lewis a.
abstract: Sialyl Lewis antigens are selectin ligands involved in leukocyte trafficking and cancer metastasis. Biosynthesis of these selectin ligands occurs by the sequential actions of several glycosyltransferases in the Golgi apparatus following synthesis of the protein backbone in the endoplasmic reticulum. In this study, we examine how the synthesis of sialyl Lewis a (sLe(a)) is regulated in prostatic cells and identify a mucin that carries this glycotope. We treat human prostatic cells including one normal and three cancerous cells with histone deacetylase inhibitors, valproic acid, tricostatin A (TSA), and suberoylanilide hydroxamic acid (SAHA), and then monitor the expression of sLe(a). We have found that SAHA enhances the production of sLe(a) in normal prostatic RWPE-1 cells but not prostatic cancer cells. Employing siRNA technology and co-immunoprecipitation, we show that the sLe(a) is associated with MUC1, which is confirmed by confocal immunofluorescence microscopy and proximity ligation assay. The SAHA-induced production of sLe(a) in RWPE-1 cells is resulted from upregulation of B3GALT1 gene via enhancement of acetylated histone-3 and histone-4. Interestingly, PC3 and LNCaP C-81 cells do not produce detectable amounts of sLe(a) despite expressing high levels of B3GALT1. However, the MUC1-associated sLe(a) is generated in these cells after introduction of MUC1 cDNA. We conclude that the synthesis of sLe(a) is controlled by not only peptide backbone of the glycoprotein but also glycoprotein-specific glycosyltransferases involved in the synthesis of sLe(a). Further, the SAHA induction of this selectin ligand in normal prostatic cells may pose a potentially serious side effect of this drug recently approved by the US Food and Drug Administration.
authors: Department of Research Service, Veterans Administration Nebraska-Western Iowa Health Care System, Omaha, Nebraska, United States of America.
authors: Vishwanath B
authors: VB
authors: Chachadi
authors: Mohamed F
authors: MF
authors: Ali
authors: Pi-Wan
authors: PW
authors: Cheng
mesh_terms: D018395:CA-19-9 Antigen; D002460:Cell Line; D006023:Glycoproteins / Q000276:immunology / Q000378:metabolism; D016695:Glycosyltransferases / Q000378:metabolism; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology; D006657:Histones / Q000276:immunology / Q000378:metabolism; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D008297:Male; D018396:Mucin-1 / Q000096:biosynthesis* / Q000276:immunology / Q000378:metabolism; D009844:Oligosaccharides / Q000276:immunology / Q000378:metabolism*; D011467:Prostate / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000276:immunology / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014635:Valproic Acid / Q000494:pharmacology; D000077337:Vorinostat
chemical_list: D018395:CA-19-9 Antigen; D006023:Glycoproteins; D056572:Histone Deacetylase Inhibitors; D006657:Histones; D006877:Hydroxamic Acids; C060192:MUC1 protein, human; D018396:Mucin-1; D009844:Oligosaccharides; C012589:trichostatin A; D000077337:Vorinostat; D014635:Valproic Acid; D016695:Glycosyltransferases